Jump to content

Michael Hemann

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Cydebot (talk | contribs) at 14:36, 9 October 2016 (Robot - Moving category People from Cleveland, Ohio to Category:People from Cleveland per CFD at Wikipedia:Categories for discussion/Log/2016 September 6.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Michael Thomas Hemann, Ph.D., born in Cleveland, Ohio in 1971, is a cancer geneticist and associate professor in the David H. Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology.

The research in Hemann's laboratory focuses on identification and characterization of genes involved in tumor formation, cancer progression, and chemotherapeutic response.[1][2][3]

Publications

  • Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT (November 2010). "Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy". Proc Natl Acad Sci U S A. 107 (48): 20786–91. doi:10.1073/pnas.1011409107. PMC 2996428. PMID 21068376.
  • Gilbert LA, Hemann MT (October 2010). "DNA damage-mediated induction of a chemoresistant niche". Cell. 143 (3): 355–66. doi:10.1016/j.cell.2010.09.043. PMC 2972353. PMID 21029859.
  • Doles J, Hemann MT (February 2010). "Nek4 status differentially alters sensitivity to distinct microtubule poisons". Cancer Res. 70 (3): 1033–41. doi:10.1158/0008-5472.CAN-09-2113. PMC 2946156. PMID 20103636.
  • Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT (October 2009). "In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression". Nat. Genet. 41 (10): 1133–7. doi:10.1038/ng.451. PMC 2756700. PMID 19783987.
  • Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT (August 2009). "The combined status of ATM and p53 link tumor development with therapeutic response". Genes Dev. 23 (16): 1895–909. doi:10.1101/gad.1815309. PMC 2725944. PMID 19608766.

References

  1. ^ "Scientists reveal cancer's hiding spots". Sify. 29 October 2010. Retrieved 19 December 2012.
  2. ^ Hirsch, Jen (8 August 2009). "Genetic Profiling of Tumors Could Have 'Immediate Impact' on Treating Cancer". Medical News Today. Retrieved 19 December 2012.
  3. ^ "Cancer cells may be protected post-chemo". UPI. 1 November 2010. Retrieved 19 December 2012.